- 6-SUBSTITUTED PYRIDAZINE COMPOUNDS AS SMARCA2 AND/OR SMARCA4 DEGRADERS
-
The present invention provides 6-substituted pyridazine compounds of formula (I), which are therapeutically useful as SMARCA2 and/or SMARCA4 degraders. These compounds are useful in the treatment and/or delaying progression of diseases or disorders dependent upon SMARCA2 and/or SMARCA4 in a subject. The present invention also provides preparation of the compounds and pharmaceutical compositions comprising at least one of the compounds of formula (I) or a pharmaceutically acceptable salt, or a stereoisomer or a tautomer or a prodrug thereof.
- -
-
Page/Page column 70; 71
(2022/02/15)
-
- Challenges in the development of an M4 PAM preclinical candidate: The discovery, SAR, and biological characterization of a series of azetidine-derived tertiary amides
-
Herein we describe the continued optimization of M4 positive allosteric modulators (PAMs) within the 5-amino-thieno[2,3-c]pyridazine series of compounds. In this letter, we disclose our studies on tertiary amides derived from substituted azetidines. This series provided excellent CNS penetration, which had been challenging to consistently achieve in other amide series. Efforts to mitigate high clearance, aided by metabolic softspot analysis, were unsuccessful and precluded this series from further consideration as a preclinical candidate. In the course of this study, we found that potassium tetrafluoroborate salts could be engaged in a tosyl hydrazone reductive cross coupling reaction, a previously unreported transformation, which expands the synthetic utility of the methodology.
- Tarr, James C.,Wood, Michael R.,Noetzel, Meredith J.,Melancon, Bruce J.,Lamsal, Atin,Luscombe, Vincent B.,Rodriguez, Alice L.,Byers, Frank W.,Chang, Sichen,Cho, Hyekyung P.,Engers, Darren W.,Jones, Carrie K.,Niswender, Colleen M.,Wood, Michael W.,Brandon, Nicholas J.,Duggan, Mark E.,Jeffrey Conn,Bridges, Thomas M.,Lindsley, Craig W.
-
p. 5179 - 5184
(2017/11/03)
-